Back to today’s briefing

Story perspectives

Daraxonrasib Doubles Pancreatic Cancer Survival, NEJM Reports

6/3/2026

38 5 Full Breakdown

Summary

Story summary

Revolution Medicines said daraxonrasib more than doubled pancreatic cancer patient survival in a trial presented at the American Society of Clinical Oncology meeting in Chicago.
The trial results were published simultaneously in the New England Journal of Medicine.
Physician Rachna Shroff, a pancreatic cancer specialist at the University of Arizona Cancer Center, began crying after learning the findings in April.

1 of 1

Story summary

Revolution Medicines said daraxonrasib more than doubled pancreatic cancer patient survival in a trial presented at the American Society of Clinical Oncology meeting in Chicago.
The trial results were published simultaneously in the New England Journal of Medicine.
Physician Rachna Shroff, a pancreatic cancer specialist at the University of Arizona Cancer Center, began crying after learning the findings in April.